Literature DB >> 8756381

Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine.

E Bruera1, J Pereira, S Watanabe, M Belzile, N Kuehn, J Hanson.   

Abstract

BACKGROUND: When a change of opioid is considered, equianalgesic dose tables are used. These tables generally propose a dose ratio of 5:1 between morphine and hydromorphone. In the case of a change from subcutaneous hydromorphone to methadone, dose ratios ranging from 1:6 to 1:10 are proposed. The purpose of this study was to review the analgesic dose ratios for methadone compared with hydromorphone.
METHODS: In a retrospective study, 48 cases of medication changes from morphine to hydromorphone, and 65 changes between hydromorphone and methadone were identified. the reason for the change, the analgesic dose, and pain intensity were obtained.
RESULTS: The dose ratios between morphine and hydromorphone and vice versa were found to be 5.33 and 0.28, respectively (similar to expected results). However, the hydromorphone/methadone ratio was found to be 1.14:1 (5 to 10 times higher than expected). Although the dose ratios of hydromorphone/morphine and vice versa did not change according to a previous opioid dose, the hydromorphone/methadone ratio correlated with total opioid dose (correlation coefficient = 0.41 P < 0.001) and was 1.6 (range, 0.3-14.4) in patients receiving more than 330 mg of hydromorphone per day prior to the change, versus 0.95 (range, 0.2-12.3) in patients receiving ae330 mg of hydromorphone per day (P = 0.023).
CONCLUSIONS: These results suggest that only partial tolerance develops between methadone and hydromorphone. Methadone is much more potent than previously described and any change should start at a lower equivalent dose.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8756381     DOI: 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  49 in total

1.  Methadone: the question or the answer for US opioid therapy and pharmaco-economics?

Authors:  E D Dickerson
Journal:  Support Care Cancer       Date:  2001-11       Impact factor: 3.603

2.  Gaps and junctions between clinical experience and theoretical framework in the use of opioids.

Authors:  Marianne Kloke
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

3.  Advertisement woes.

Authors:  George Vautour
Journal:  CMAJ       Date:  2005-12-06       Impact factor: 8.262

Review 4.  Methadone for treatment of cancer pain.

Authors:  John Bryson; Anoo Tamber; Dori Seccareccia; Camilla Zimmermann
Journal:  Curr Oncol Rep       Date:  2006-07       Impact factor: 5.075

Review 5.  Strategies for the treatment of cancer pain in the new millennium.

Authors:  C Ripamonti; E D Dickerson
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 6.  Underutilisation of opioids in elderly patients with chronic pain: approaches to correcting the problem.

Authors:  Kirsten Auret; Stephan A Schug
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

7.  The poor use of methadone in Italian hospices.

Authors:  Sebastiano Mercadante; Alessandro Valle; Cristina Agnelotti; Amanda Caruselli
Journal:  Support Care Cancer       Date:  2013-03-16       Impact factor: 3.603

8.  Standard therapy with opioids in chronic pain management : ORTIBER study.

Authors:  Antonio Gatti; Carlo Reale; Roberto Occhioni; Marta Luzi; Alessandra Canneti; Claudia De Polo; Martina Gubernari; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

9.  Switching from methadone to a different opioid: what is the equianalgesic dose ratio?

Authors:  Paul W Walker; Shana Palla; Be-Lian Pei; Guddi Kaur; Karen Zhang; Jeanine Hanohano; Mark Munsell; Eduardo Bruera
Journal:  J Palliat Med       Date:  2008-10       Impact factor: 2.947

10.  An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.

Authors:  Magdi Hanna; Alberto Tuca; John Thipphawong
Journal:  BMC Palliat Care       Date:  2009-09-15       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.